Biology Reference
In-Depth Information
Shanley JD, Wu CA (2003) Mucosal immunization with a replication-deficient adenovirus vector
expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity.
Vaccine 21:2632-2642
Shanley JD, Wu CA (2005) Intranasal immunization with a replication-deficient adenovirus vec-
tor expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic
immunity. Vaccine 23:996-1003
Shen S, Wang S, Britt WJ, Lu S (2007) DNA vaccines expressing glycoprotein complex II anti-
gens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus
(HCMV) isolates. Vaccine 25:3319-3327
Shimamura M, Mach M, Britt WJ (2006) Human cytomegalovirus infection elicits a glycoprotein
M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80:4591-4600
Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, Stroncek DF (2007) CMV pp65 and
IE-1 T cell epitopes recognized by healthy subjects. J Transl Med 5:17
Soderberg-Naucler C (2006) Does cytomegalovirus play a causative role in the development of
various inflammatory diseases and cancer? J Intern Med 259:219-246
Spaete RR (1991) A recombinant subunit vaccine approach to HCMV vaccine development.
Transplant Proc 23 [Suppl 3]:90-96
Stratton KR, Durch JS, Lawrence RS (1999) Vaccines for the 21st century: a tool for decisionmak-
ing, Committee to Study Priorities for Vaccine Development, Division of Health Promotion
and Disease Prevention, Institute of Medicine, Washington, DC
Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F, Sleath PR, Grabstein KH,
Hosken NA, Kern F, Nelson JA, Picker LJ (2005) Broadly targeted human cytomegalovirus-
specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.
J Exp Med 202:673-685
Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I, Ganz PR (1999)
Development of biopharmaceuticals in plant expression systems: cloning, expression and
immunological reactivity of human cytomegalovirus glycoprotein B (UL55) in seeds of trans-
genic tobacco. Vaccine 17:3020-3029
Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Pasa-Tolic L, Wang D, Camp DG
2nd, Rodland K, Wiley S, Britt W, Shenk T, Smith RD, Nelson JA (2004) Identification of
proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol
78:10960-10966
Vilalta A, Mahajan RK, Hartikka J, Rusalov D, Martin T, Bozoukova V, Leamy V, Hall K, Lalor P,
Rolland A, Kaslow DC (2005) I. Poloxamer-formulated plasmid DNA-based human cytomeg-
alovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum
Gene Ther 16:1143-1150
Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995)
Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone
marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038-1044
Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial
and endothelial cell tropism. Proc Natl Acad Sci USA 102:18153-18158
Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, Daftarian P, Longmate J, Britt WJ,
Diamond DJ (2004) Recombinant modified vaccinia virus Ankara expressing a soluble form
of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains
of human cytomegalovirus. J Virol 78:3965-3976
Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ (2006) Attenuated
poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV
infection. J Clin Virol 35:324-331
Whitley RJ (2004) Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp
Med Biol 549:155-160
Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG (1996) The human
cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein
pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569-7579
